Efficacy of probiotic treatment with <i>Bifidobacterium longum 536</i> for induction of remission in active ulcerative colitis: A randomized, double‐blinded, placebo‐controlled multicenter trial

Abstract

Supplementation with BB536 was well tolerated and reduced UCDAI scores, EI and Mayo subscores after 8 weeks in Japanese patients with mild to moderately active UC.